We are looking for partnering opportunities on new assets (small molecules, biologics, or advanced therapies) in clinical or preclinical development stages that could be used for the treatment of dermatological conditions.
Preferably, the assets should target immuno-inflammatory pathways with rationale for dermatological indications, such as atopic dermatitis, hidradenitis suppurativa, alopecia areata, and vitiligo, or be suitable for non-melanoma skin cancer, or rare dermatological indications.
New assets in clinical or preclinical development stages
What we offer
Access to our expertise in dermatological R&D
A partnership opportunity
Finding innovative therapies for patients
For scientists at biotechs, start-ups, pharmaceutical companies, Universities, and eesearch institutions
Open from 20/07/22 to 04/11/22
Pharmacological profile of your asset & partnership opportunity